About Us
Leadership
HomeAbout UsLeadership
-
- President (CEO)
- Sang Hoon Lee, Ph.D.
- Further information
-
- Chief Financial Officer
- Jaecheon Jerry Lee, MBA
- Further information
-
- Head of R&D
- Weon Kyoo You, Ph.D.
- Further information
-
- Head of Discovery
- Jaeho Jung, Ph.D.
- Further information
-
- Head of Early Development
- Jonghwa Won, Ph.D.
- Further information
-
- Chief Operations Officer
- Jungdae Kim, MBA
- Further information
Chief Executive Officer and President
Sang Hoon Lee, Ph.D.
Dr. Lee founded ABL Bio in February 2016 with the vision to build a company that offers patients a better life based on innovative science.
Recognizing that bispecific antibodies are the key to next-generation therapeutics, Dr. Lee has focused on diversifying ABL’s portfolio of bispecific antibody-based treatments for cancer and neurodegeneration.
Under his leadership, ABL has advanced four bispecific antibodies into clinical trials, demonstrating unprecedented speed and commitment among South Korean biotechnology companies.
Prior to ABL, Dr. Lee co-founded PharmAbcine where he oversaw all research and development for antibody therapeutic projects. Before that, he was responsible for drug discovery and preclinical development as the Head of the Bio Division at Hanwha Chemical.
Dr. Lee also brings years of experience from global biopharmaceutical companies, including Chiron(Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies.
Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School and UCSF. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.
Prior to ABL, Dr. Lee co-founded PharmAbcine where he oversaw all research and development for antibody therapeutic projects. Before that, he was responsible for drug discovery and preclinical development as the Head of the Bio Division at Hanwha Chemical.
Dr. Lee also brings years of experience from global biopharmaceutical companies, including Chiron(Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies.
Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School and UCSF. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.
Executive Vice President, Chief Financial Officer
Jerry Jaecheon Lee, MBA
Jerry is a founding member of ABL Bio, where he is responsible for all managerial and financial functions of the company, including financial strategy, capital investment, accounting, investor and public relations and risk-managing. He also oversees all global and domestic partnership activities.
Jerry previously served as Vice President of the Bio Division at Hanwha Chemical, where he supervised the Division’s corporate strategy. Before joining Hanwha, Jerry was a Director at Deloitte Consulting where he led life-science and healthcare practices. He began his professional career as an associate consultant at Oliver Wyman.
Jerry holds an M.B.A. and M.H.S.A. from the University of Michigan and received his B.A. in Business Administration from Korea University.
Jerry previously served as Vice President of the Bio Division at Hanwha Chemical, where he supervised the Division’s corporate strategy. Before joining Hanwha, Jerry was a Director at Deloitte Consulting where he led life-science and healthcare practices. He began his professional career as an associate consultant at Oliver Wyman.
Jerry holds an M.B.A. and M.H.S.A. from the University of Michigan and received his B.A. in Business Administration from Korea University.
Executive Vice President, Chief Scientific Officer
Weon Kyoo You, Ph.D.
Dr. You heads all research and development strategies at ABL Bio. He leads efforts to strengthen the company’s portfolio of bispecific antibody cancer immunotherapies and neurodegenerative disease therapies.
Dr. You has extensive experience in leading antibody projects from discovery to nonclinical stages. Throughout his career, he has achieved more than 30 scientific publications and multiple worldwide patents. Before ABL, Dr. You was a Principal Scientist at Hanwha Chemical, where he managed the development of novel anti-cancer therapeutic antibodies. Prior to Hanwha, he worked as a researcher at the Sanford-Burnham Medical Research Institute. In his earlier career, he developed novel therapeutics at the Mogam Biotechnology Research Institute and Iljin Materials.
Dr. You is a graduate of Yonsei University with a Ph.D., M.S. and B.S. in Biochemistry. He completed his postdoctoral fellowship at the University of California, San Francisco.
Dr. You has extensive experience in leading antibody projects from discovery to nonclinical stages. Throughout his career, he has achieved more than 30 scientific publications and multiple worldwide patents. Before ABL, Dr. You was a Principal Scientist at Hanwha Chemical, where he managed the development of novel anti-cancer therapeutic antibodies. Prior to Hanwha, he worked as a researcher at the Sanford-Burnham Medical Research Institute. In his earlier career, he developed novel therapeutics at the Mogam Biotechnology Research Institute and Iljin Materials.
Dr. You is a graduate of Yonsei University with a Ph.D., M.S. and B.S. in Biochemistry. He completed his postdoctoral fellowship at the University of California, San Francisco.
Chief Medical & Clinical Development Officer
Eunkyung Kim, M.D., Ph.D.
Dr. Kim leads clinical development at ABL Bio. She is responsible for setting clinical development strategies based on the asset profiles and unmet medical needs. She manages the clinical projects and team, while collaborating with various partners to accelerate clinical development of ABL Bio’s portfolio in the relevant disease areas.
Dr. Kim has broad experience in drug development, especially in the oncology therapeutic area. Before joining ABL Bio, she worked at the eminent multinational pharmaceutical companies since 2008. Dr. Kim led the oncology clinical development team for Bristol-Myers-Squibb (BMS) Japan and served as an oncology medical specialist for Asia pacific countries. Prior to BMS, she worked at Novartis Oncology, leading global and local development and medical affairs for Korea.
Dr. Kim is a graduate of Seoul National University with a Ph.D., M.S., and M.D. in College of Medicine. She was also educated at University of Basel’s European Center for Pharmaceutical Medicine in Switzerland.
Dr. Kim has broad experience in drug development, especially in the oncology therapeutic area. Before joining ABL Bio, she worked at the eminent multinational pharmaceutical companies since 2008. Dr. Kim led the oncology clinical development team for Bristol-Myers-Squibb (BMS) Japan and served as an oncology medical specialist for Asia pacific countries. Prior to BMS, she worked at Novartis Oncology, leading global and local development and medical affairs for Korea.
Dr. Kim is a graduate of Seoul National University with a Ph.D., M.S., and M.D. in College of Medicine. She was also educated at University of Basel’s European Center for Pharmaceutical Medicine in Switzerland.
Executive Vice President, Chief of Discovery
Jaeho Jung, Ph.D.
Dr. Jung is responsible for discovery at ABL Bio. He has a demonstrated background in oncology and immunology with experience in the execution of preclinical studies in a regulatory industry setting.
Prior to this role, Dr. Jung was a Principal Scientist at Agensys, Inc., where he managed the development of pre-clinical in vivo tumor models, evaluated investigational immuno-oncology therapeutics and antibody drug conjugates by conducting efficacy, PK, PD and MOA studies. He was previously the R&D director at HepaHope where he led the preclinical study planning and execution of IND-enabling in vitro and in vivo studies. Earlier in his career, Dr. Jung was involved in antibody discovery and tumor immunology at Biogen Idec.
He gained his Ph.D. in Immunology at the Ohio State University and conducted his postdoctoral research at Stanford University and the Ochsner Clinic Foundation. He holds a M.S. in Microbiology and B.S. in Biology at Konkuk University.
Prior to this role, Dr. Jung was a Principal Scientist at Agensys, Inc., where he managed the development of pre-clinical in vivo tumor models, evaluated investigational immuno-oncology therapeutics and antibody drug conjugates by conducting efficacy, PK, PD and MOA studies. He was previously the R&D director at HepaHope where he led the preclinical study planning and execution of IND-enabling in vitro and in vivo studies. Earlier in his career, Dr. Jung was involved in antibody discovery and tumor immunology at Biogen Idec.
He gained his Ph.D. in Immunology at the Ohio State University and conducted his postdoctoral research at Stanford University and the Ochsner Clinic Foundation. He holds a M.S. in Microbiology and B.S. in Biology at Konkuk University.
Executive Vice President, Chief Translational Research Officer
Jonghwa Won, Ph.D.
Dr. Won is recognized for her strong experience in drug discovery and development. At ABL, she oversees all target selection, MOA, translation and clinical studies.
Dr. Won brings over 20 years of experience from the MOGAM Institute. She was Head of the Translation Unit at the MOGAM Institute for Biomedical Research (MIBR), where she managed projects regarding targeted therapeutics, immune checkpoint inhibitors and T cell-redirecting antibodies. She also previously directed the MOGAM Biotechnology Research Institute, supervising early-stage oncology programs and advancing them to Phase 2 clinical stages.
She earned a Ph.D. and M.S. in Immunobiology at Iowa State University. She received her B.S. in Biology Education from Seoul National University and graduated with honors.
Dr. Won brings over 20 years of experience from the MOGAM Institute. She was Head of the Translation Unit at the MOGAM Institute for Biomedical Research (MIBR), where she managed projects regarding targeted therapeutics, immune checkpoint inhibitors and T cell-redirecting antibodies. She also previously directed the MOGAM Biotechnology Research Institute, supervising early-stage oncology programs and advancing them to Phase 2 clinical stages.
She earned a Ph.D. and M.S. in Immunobiology at Iowa State University. She received her B.S. in Biology Education from Seoul National University and graduated with honors.
Executive Vice President, Chief Operations Officer
Jungdae Kim, MBA
Since joining ABL in 2019, Mr. Kim has been responsible for all aspects of the human resources agenda, including talent acquisition, compensation, benefits, employee relations and inclusive working environment.
Mr. Kim brings nearly three decades of experience from Hewlett-Packard Enterprise Korea. He held various leadership roles covering a broad range of areas, including channel service management, account management, customer experience, business strategy planning and field development. He also supervised learning and development programs to enhance organizational effectiveness.
He obtained his M.B.A. from Sogang University and bachelor’s degrees in Aeronautical Science & Flight Operation and Electric Engineering from the Korea Aerospace University
Mr. Kim brings nearly three decades of experience from Hewlett-Packard Enterprise Korea. He held various leadership roles covering a broad range of areas, including channel service management, account management, customer experience, business strategy planning and field development. He also supervised learning and development programs to enhance organizational effectiveness.
He obtained his M.B.A. from Sogang University and bachelor’s degrees in Aeronautical Science & Flight Operation and Electric Engineering from the Korea Aerospace University